An observational study in Rheumatic Diseases, Abuse Neglect and Abuse, sponsored by National Institute of Medical Sciences and Nutrition, Salvador Zubiran. Recruiting at 1 site in Mexico. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-03-12.
Sponsored by National Institute of Medical Sciences and Nutrition, Salvador Zubiran · Observational
Patients with rheumatic diseases (RD) have a relevant representation in the adult population in Mexico. RD are characterized by their chronic and progressive nature, which can impact functionality during the disease and can present various factors that can be associated with the presence of abuse, among others, economic dependence, decreased physical capacity, and need for care and support in different health processes.
Regarding abuse in patients with RD, there is little information in the literature; however, it is possible that the prevalence could be similar to that of the occurrence in older adults since both populations share important states of vulnerability.
The study aimed to identify the prevalence of abuse in patients with RD. The study will be conducted in two phases: the first one in which the GAS will be adapted for patients with RD, and this version will be validated in a population of our Institute, and the second one in which, applying the validated instrument, the magnitude of abuse is evaluated, and the factors associated with this phenomenon among patients with RD are explored.
Patients with rheumatic diseases (RD) have a relevant representation in the adult population in Mexico. RD are characterized by their chronic and progressive nature, which can impact functionality during the disease and can present various factors that can be associated with the presence of abuse, among others, economic dependence, decreased physical capacity, and need for care and support in different health processes.
In 1970, the phenomenon of abuse in geriatric patients was described for the first time as a phenomenon identified as a public health problem and an issue of human rights violation.
In 2012 Giraldo-Rodríguez developed and validated the Geriatric Abuse Scale (GAS), an instrument that, with adequate psychometric properties, reported a prevalence of abuse of 10.28% in Mexico.
Regarding abuse in patients with RD, there is little information in the literature; however, it is possible that the prevalence could be similar to that of the occurrence in older adults since both populations share important states of vulnerability.
The study aimed to identify the prevalence of abuse in patients with RD. The study will be conducted in two phases: the first one in which the GAS will be adapted for patients with RD, and this version will be validated in a population of our Institute, and the second one in which, applying the validated instrument, the magnitude of abuse is evaluated, and the factors associated with this phenomenon among patients with RD are explored.
264 studies on the registry are indexed under Rheumatic Diseases; 60 are open to participants now.
This study's planned enrollment of 244 is close to the median of 225 across 90 observational studies indexed under Rheumatic Diseases.
Browse Rheumatic Diseases studies →National Institute of Medical Sciences and Nutrition, Salvador Zubiran is the lead sponsor of 16 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All the rheumatic diseases outpatients from the National Institute of Medical Sciences
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
All the rheumatic diseases outpatients from the National Institute of Medical Sciences
Other: Rheumatic diseases Mistreatment Scale (RDMS) · Other: Health Assessment Questionnaire (HAQ) · Other: Depression, Anxiety and Stress Scale (DASS-21) · Other: Brief Resilient Coping Scale · Other: WHOQOL-BREF · Other: Routine assessment of patient index data 3 (RAPID-3) · Other: Big Five Inventory · Other: Family APGAR Questionnaire
In 2012 Giraldo-Rodríguez developed and validated the Geriatric Mistreatment Scale (GAS), prior to its application, translation, cultural adaptation, and validation were performed.
Also known as: RD-MS
The HAQ is based on five patient-centered dimensions: disability, pain, medication effects, costs of care, and mortality
Also known as: HAQ
DASS-21 is a set of three self-report scales designed to measure the emotional states of depression, anxiety, and stress. Each of the three DASS-21 scales contains 7 items, divided into subscales with similar content
Also known as: DASS-21
Brief Resilient Coping Scale is a 4-item measure designed to capture tendencies to cope with stress in a highly adaptive manner
Also known as: BRCS
WHOQOL-BREF is a 26-item instrument consisting of four domains: physical health, psychological health, social relationships, and environmental health; it also contains QOL and general health items
RAPID- 3 measures: function, pain, and patient global estimate of status. Each of the 3 individual measures is scored 0 to 10, for a total of 30
Also known as: RAPID-3
The BFI-10 is a 10-item scale measuring the Big Five personality traits Extraversion, Agreeableness, Conscientiousness, Emotional Stability, and Openness.
Also known as: BFI-10
Family APGAR questionnaire is used to evaluate family function, in the context of family medical care
Also known as: APGAR
Number of Mexican patients with RD who will present the phenomenon of mistreatment
Identify the percentage of patients with rheumatic diseases that present mistreatment using the instrument developed by Giraldo-Rodríguez et al (translation, cultural adaptation, and validation performed)
Time frame: At inclusion (baseline moment) (cross-sectional study)
Identify factors associated with mistreatment among patients with rheumatic diseases
Identify factors associated with mistreatment among patients with rheumatic diseases using an instrument locally development
Time frame: At inclusion (baseline moment) (cross-sectional study)
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Institute of Medical Sciences and Nutrition, Salvador Zubiran